DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Hämatologische Neoplasien » NHL

Alle Linien

B-NHL 2013
B-NHL 2013 - Behandlungsprotokoll der NHL-BFM und der NOPHO-Studiengruppen für reife aggressive B-Zell-Lymphome und -Leukämien bei Kindern und Jugendlichen (Aktiv)

CZAR-1
fficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1) (Aktiv)

JCAR017-BCM-004
JE A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (Aktiv)

M22-132
A study to evaluate adverse events and change in disease activity of subcutaneous (SC) epcoritamab in combination with oral and intravenous anti-neoplastic agents in adult participants with Non-Hodgkin Lymphoma Phase 1b/2, open-label study to evaluate safety and tolerability of Epcoritamab in combination with anti-neoplastic agents in subjects with Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents (Aktiv)

POLE-1
Efficacy of pembrolizumab in patients with marginal zone lymphoma (Aktiv)

Pix in DLBCL first line
R-CPOP as first line therapy (Aktiv)

Erstlinie

NHL 3-2004
Therapy Optimisation for the Treatment of Hairy Cell Leukemia (Aktiv)

Zweitlinie oder später

67856633LYM1001
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)

CHARLY
Study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CVOB560A12101
A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma. (Aktiv)

GC-LTFU-001
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)

Lymrit-37-01
A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. (Aktiv)

MB-CART19.1 r/r CD19+ BCM
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (Aktiv)

PCYC-1123-CA
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab (Aktiv)

Pix in DLBCL first line
R-CPOP as first line therapy (Aktiv)

R1979-ONC-1625
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (Aktiv)

REGN1979-HM-1333
This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de